Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

Blood Cancer Journal

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and...

  • 123456 Profile photo of Madelyn

    This study shows that production of neutralizing antibodies against COVID are low in patients with myeloma, and impaired especially in patients receiving anti CD38 antibodies or belantamab.